Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Factors associated with results and conclusions of trials of thiazolidinediones.

Rattinger G, Bero L.

PLoS One. 2009 Jun 8;4(6):e5826. doi: 10.1371/journal.pone.0005826.

3.

Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation.

Czoski-Murray C, Warren E, Chilcott J, Beverley C, Psyllaki MA, Cowan J.

Health Technol Assess. 2004 Apr;8(13):iii, ix-x, 1-91. Review.

4.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
5.

Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.

Hemmingsen B, Schroll JB, Lund SS, Wetterslev J, Gluud C, Vaag A, Sonne DP, Lundstrøm LH, Almdal T.

Cochrane Database Syst Rev. 2013 Apr 30;(4):CD009008. doi: 10.1002/14651858.CD009008.pub2. Review. Update in: Cochrane Database Syst Rev. 2015;(7):CD009008.

PMID:
23633364
6.

Treatment of periodontal disease for glycaemic control in people with diabetes mellitus.

Simpson TC, Weldon JC, Worthington HV, Needleman I, Wild SH, Moles DR, Stevenson B, Furness S, Iheozor-Ejiofor Z.

Cochrane Database Syst Rev. 2015 Nov 6;(11):CD004714. doi: 10.1002/14651858.CD004714.pub3. Review.

PMID:
26545069
7.

A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors.

Chiquette E, Ramirez G, Defronzo R.

Arch Intern Med. 2004 Oct 25;164(19):2097-104.

PMID:
15505122
8.

Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments.

Roseman M, Milette K, Bero LA, Coyne JC, Lexchin J, Turner EH, Thombs BD.

JAMA. 2011 Mar 9;305(10):1008-17. doi: 10.1001/jama.2011.257. Review.

PMID:
21386079
9.
10.

Oral antidiabetic agents: current role in type 2 diabetes mellitus.

Krentz AJ, Bailey CJ.

Drugs. 2005;65(3):385-411. Review.

PMID:
15669880
11.

Glitazones in type 2 diabetes: an update.

[No authors listed]

Drug Ther Bull. 2008 Apr;46(4):25-9. doi: 10.1136/dtb.2008.03.0008. Review.

PMID:
18403615
12.

Insulin and oral agents for managing cystic fibrosis-related diabetes.

Onady GM, Stolfi A.

Cochrane Database Syst Rev. 2016 Apr 18;4:CD004730. doi: 10.1002/14651858.CD004730.pub4. Review.

PMID:
27087121
13.

Glitazone use associated with diabetic macular edema.

Fong DS, Contreras R.

Am J Ophthalmol. 2009 Apr;147(4):583-586.e1. doi: 10.1016/j.ajo.2008.10.016.

PMID:
19181303
14.

Colesevelam for type 2 diabetes mellitus.

Ooi CP, Loke SC.

Cochrane Database Syst Rev. 2012 Dec 12;12:CD009361. doi: 10.1002/14651858.CD009361.pub2. Review.

PMID:
23235674
15.

A 26-week, placebo- and pioglitazone-controlled, dose-ranging study of rivoglitazone, a novel thiazolidinedione for the treatment of type 2 diabetes.

Truitt KE, Goldberg RB, Rosenstock J, Chou HS, Merante D, Triscari J, Wang AC.

Curr Med Res Opin. 2010 Jun;26(6):1321-31. doi: 10.1185/03007991003715079.

PMID:
20370378
16.

Association of industry sponsorship to published outcomes in gastrointestinal clinical research.

Brown A, Kraft D, Schmitz SM, Sharpless V, Martin C, Shah R, Shaheen NJ.

Clin Gastroenterol Hepatol. 2006 Dec;4(12):1445-51.

PMID:
17101295
17.
18.

Association of industry funding with the outcome and quality of randomized controlled trials of drug therapy for rheumatoid arthritis.

Khan NA, Lombeida JI, Singh M, Spencer HJ, Torralba KD.

Arthritis Rheum. 2012 Jul;64(7):2059-67. doi: 10.1002/art.34393.

19.

[Glucose-independent impact of the glitazones on the cardiovascular outcome].

Hanefeld M.

MMW Fortschr Med. 2005 Jan 13;147(1-2):37-9. Review. German.

PMID:
15704569
20.
Items per page

Supplemental Content

Support Center